
Genital Herpes - Pipeline Insight, 2024
Description
Genital Herpes - Pipeline Insight, 2024
DelveInsight’s, “Genital Herpes - Pipeline Insight, 2024,” report provides comprehensive insights about 26+ companies and 28+ pipeline drugs in Genital Herpes pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Genital Herpes: Overview
Herpes genitalis is among the most common sexually transmitted infections. It is caused by the herpes simplex virus type 2 (HSV-2) and also, increasingly, the herpes simplex virus type 1 (HSV-1). Both organisms are enveloped DNA viruses that are sensitive to disinfectants and environmental factors 1. Due to marked genetic homology between HSV-1 and HSV-2 numerous biological similarities and antigenic cross-reactions between the viruses exist. Type-specific epitopes include the viral glycoproteins (g) gG (HSV-1 and HSV-2) and gC (HSV-1). The primary mode of transmission of both HSV-1 and HSV-2 is through direct contact. Initial infection with HSV-1 occurs most often during childhood following the disappearance of maternal antibodies during the first year of life.
""Genital Herpes - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Genital Herpes pipeline landscape is provided which includes the disease overview and Genital Herpes treatment guidelines. The assessment part of the report embraces, in depth Genital Herpes commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence in Genital Herpes R&D. The therapies under development are focused on novel approaches to treat/improve in Genital Herpes.
Genital Herpes Emerging Drugs
- Pritelivir: AiCuris
- UB 621: United BioPharma
Further product details are provided in the report……..
Genital Herpes: Therapeutic Assessment
This segment of the report provides insights about the different Genital Herpes drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Genital Herpes
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Genital Herpes: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Genital Herpes therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Genital Herpes drugs.
Genital Herpes Report Insights
- Genital Herpes Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Genital Herpes drugs?
- How many Genital Herpes drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Genital Herpes?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Genital Herpes?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Genital Herpes and their status?
- What are the key designations that have been granted to the emerging drugs?
- AiCuris
- United BioPharma
- Heidelberg ImmunoTherapeutics
- Immune System Regulation
- Admedus Immunotherapies
- Brandenburg Antiinfektiva GmbH
- Starpharma
- BioNTech
- GlaxoSmithKline
- Auritec Pharmaceuticals
- JN-International Medical Corporation
- BlueWillow Biologics
- Moderna Therapeutics
- Assembly Biosciences
- Shulov Institute for Science LTD
- X-Vax Technology
- Vaxxit
- Nanoviricides
- Pritelivir
- UB 621
- HDIT 101
- ISR048
- HSV-2 DNA Vaccine
- Aspidasept
- VivaGel
- BNT 163
- GSK 3943104A
- Aciclovir Intravaginal Ring
- Genital herpes Vaccine
- NE HSV-2 vaccine
- mRNA 1608
- HSV-2 Long-Acting Helicase Inhibitor
- ZEP-3
- delta gD-2
- Attenuated vaccine against HSV 1&2
- HSV “Genital lesions” Skin cream/Lotion
Table of Contents
107 Pages
- Introduction
- Executive Summary
- Genital Herpes : Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Genital Herpes – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Pritelivir: AiCuris
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- UB 621: United BioPharma
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- Comparative Analysis
- HSV-2 DNA Vaccine: Admedus Immunotherapies
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- BNT 163: BioNTech SE
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Genital Herpes Key Companies
- Genital Herpes Key Products
- Genital Herpes -Unmet Needs
- Genital Herpes -Market Drivers and Barriers
- Genital Herpes -Future Perspectives and Conclusion
- Genital Herpes Analyst Views
- Genital Herpes Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.